He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Q2 FY25 Total Income was at Rs. 85.4 crore
This product will be manufactured at Lupin’s Nagpur facility in India
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
